|
Jun 23
|
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the company
|
|
Jun 18
|
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
|
|
May 13
|
Shareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years ago
|
|
May 9
|
ProQR Announces First Quarter 2024 Operating and Financial Results
|
|
May 8
|
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
|
|
Apr 23
|
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
|
|
Apr 22
|
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
|
|
Apr 19
|
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
|
|
Mar 14
|
ProQR Therapeutics Full Year 2023 Earnings: Misses Expectations
|
|
Mar 13
|
ProQR Announces Year End 2023 Operating and Financial Results
|
|
Jan 15
|
While institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the most
|
|
Dec 28
|
Is ProQR (PRQR) Stock a Solid Choice Right Now?
|
|
Dec 8
|
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
|
|
Sep 28
|
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
|